David Medical(300314)

Search documents
戴维医疗:截至2025年7月31日公司股东总户数约为23900户
Zheng Quan Ri Bao Wang· 2025-08-05 14:12
证券日报网讯戴维医疗(300314)8月5日在互动平台回答投资者提问时表示,截至2025年7月31日,公 司股东总户数约为23900户。 ...
戴维医疗股东户数增加4900户,户均持股1.21万股,户均持股市值17.12万元
Sou Hu Cai Jing· 2025-08-05 07:56
从8月5日公开信息显示,戴维医疗截至2025年7月31日公司股东户数为2.39万户,较上期(2025年7月18日)增加4900户,增 幅为25.79%,持股趋于分散。 从数据对比来看,戴维医疗户均持股数从上期1.52万股下降至本期1.21万股,户均持股市值从上期19.81万元下降至本期17.12 万元。上述区间,戴维医疗股价累计上涨7.48%。 截至发稿,戴维医疗报13.93元,下跌1.28%,市值40.12亿元。 最新5个统计日期,戴维医疗股东户数变动如下: 统计日期股东户数户均持股数(万股)户均持股市值(万元) 2025/07/31239001.2117.122025/07/18190001.5219.812025/07/10191001.5119.232025/06/10198001.4518.752025/05/30199001.4518.03 来源:金融界 ...
戴维医疗股价微涨0.21% 公司回应婴儿鸟巢产品功能
Sou Hu Cai Jing· 2025-08-05 00:40
Group 1 - The stock price of David Medical reached 14.11 yuan as of August 4, 2025, with an increase of 0.03 yuan from the previous trading day [1] - The company operates in the medical device sector, focusing on the research and manufacturing of infant care equipment, including incubators and radiant warmers for newborns [1] - The latest data indicates a total market capitalization of 4.064 billion yuan and a price-to-earnings ratio of 45.02 [1] Group 2 - The HLD series medical isolation pad, referred to as the "baby nest," provides tactile stimulation and a sense of security for infants, effectively regulating heart rate, respiratory rate, and improving sleep quality [1] - On August 4, there was a net outflow of 22.0897 million yuan in main funds, accounting for 1.09% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow was 18.7868 million yuan, representing 0.93% of the circulating market value [1]
戴维医疗:“婴儿鸟巢”即公司产品HLD系列医用隔离垫
Mei Ri Jing Ji Xin Wen· 2025-08-04 07:59
每经AI快讯,有投资者在投资者互动平台提问:尊敬的董秘,您好,我发现公司有个婴儿鸟巢项目被 人比喻为人工子宫,请问具体是什么作用? 戴维医疗(300314.SZ)8月4日在投资者互动平台表示,您所说的"婴儿鸟巢"即公司产品HLD系列医用 隔离垫,主要用于对病人提供一般性防护,以免受其他器械或外界的伤害,是一种可以给婴儿提供类似 子宫的触觉刺激和安全感的"鸟巢式"襁褓,能有效减慢婴儿心率、呼吸频率,延长睡眠时间,提高睡眠 质量。 (记者 张明双) ...
戴维医疗(300314)8月1日主力资金净流出2425.73万元
Sou Hu Cai Jing· 2025-08-02 09:15
Group 1 - The core viewpoint of the news highlights the financial performance and stock market activity of David Medical (戴维医疗), indicating a decline in revenue and profit for the first quarter of 2025 [1] - As of August 1, 2025, David Medical's stock closed at 14.08 yuan, down 0.91%, with a turnover rate of 11.45% and a trading volume of 164,500 hands, amounting to a transaction value of 234 million yuan [1] - The company's latest quarterly report shows total operating revenue of 121 million yuan, a year-on-year decrease of 22.00%, and a net profit attributable to shareholders of 22.57 million yuan, down 40.78% year-on-year [1] Group 2 - The company has a current ratio of 4.798, a quick ratio of 3.738, and a debt-to-asset ratio of 13.99%, indicating a strong liquidity position [1] - David Medical has made investments in 6 companies and participated in 1,465 bidding projects, showcasing its active engagement in the market [2] - The company holds 65 trademark registrations and 302 patents, along with 71 administrative licenses, reflecting its commitment to innovation and compliance [2]
戴维医疗股价震荡下行 主力资金净流出909万元
Sou Hu Cai Jing· 2025-07-31 13:21
Group 1 - The core stock price of David Medical as of July 31, 2025, closed at 14.21 yuan, down 3.00% from the previous trading day, with a trading volume of 370 million yuan [1] - The stock experienced significant volatility during the day, with a high of 14.98 yuan and a low of 14.21 yuan, resulting in a fluctuation of 5.26% [1] - David Medical specializes in the research, production, and sales of medical devices, primarily focusing on neonatal medical equipment such as incubators and radiant warmers [1] Group 2 - On July 31, the stock showed rapid fluctuations, with a rebound of over 2% within 5 minutes in the morning session, followed by a quick decline of over 2% within the next 5 minutes, indicating active market trading [1] - The net outflow of main funds was 9.0994 million yuan, accounting for 0.45% of the circulating market value, suggesting market divergence regarding the short-term outlook of the stock [1]
戴维医疗收盘下跌3.00%,滚动市盈率98.09倍,总市值40.92亿元
Sou Hu Cai Jing· 2025-07-31 10:20
7月31日,戴维医疗今日收盘14.21元,下跌3.00%,滚动市盈率PE(当前股价与前四季度每股收益总和 的比值)达到98.09倍,总市值40.92亿元。 资金流向方面,7月31日,戴维医疗主力资金净流出909.94万元,近5日总体呈流入状态,5日共流入 4271.27万元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13戴维医疗98.0971.473.4340.92亿行业平均 54.8949.974.71114.46亿行业中值37.0636.862.6754.89亿1九安医疗10.9311.060.86184.50亿2英科医疗 14.2315.351.27224.88亿3新华医疗15.7214.571.28100.77亿4山东药玻15.9516.001.83150.91亿5奥美医疗 16.2315.911.6758.64亿6振德医疗16.2415.301.0358.94亿7康德莱17.1117.121.4236.87亿8九强生物 17.3416.132.1285.89亿9维力医疗17.4318.622.1940.86亿10奥泰生物17.8318.801.4456.86亿11鱼跃医疗 19.741 ...
戴维医疗(300314)7月30日主力资金净流入2318.76万元
Sou Hu Cai Jing· 2025-07-30 08:48
天眼查商业履历信息显示,宁波戴维医疗器械股份有限公司,成立于1992年,位于宁波市,是一家以从 事医药制造业为主的企业。企业注册资本28800万人民币,实缴资本28800万人民币。公司法定代表人为 陈再宏。 通过天眼查大数据分析,宁波戴维医疗器械股份有限公司共对外投资了6家企业,参与招投标项目1463 次,知识产权方面有商标信息65条,专利信息301条,此外企业还拥有行政许可71个。 来源:金融界 金融界消息 截至2025年7月30日收盘,戴维医疗(300314)报收于14.65元,上涨2.09%,换手率 19.61%,成交量28.19万手,成交金额4.09亿元。 资金流向方面,今日主力资金净流入2318.76万元,占比成交额5.67%。其中,超大单净流出93.04万 元、占成交额0.23%,大单净流入2411.80万元、占成交额5.89%,中单净流出流入267.58万元、占成交 额0.65%,小单净流出2586.34万元、占成交额6.32%。 戴维医疗最新一期业绩显示,截至2025一季报,公司营业总收入1.21亿元、同比减少22.00%,归属净利 润2256.77万元,同比减少40.78%,扣非净利润174 ...
A股五张图:方丈都破戒了,你们有什么理由不生!
Xuan Gu Bao· 2025-07-29 10:32
Market Overview - The indices continued to rise collectively, with a significant drop in the morning followed by a recovery in sentiment in the afternoon [3] - The Shanghai Composite Index, Shenzhen Component Index, and ChiNext Index closed up by 0.33%, 0.64%, and 1.86% respectively, with over 3,000 stocks declining and more than 2,200 stocks rising [4] Optimizing Fertility - The "Implementation Plan for Childcare Subsidy System" was officially launched, providing annual subsidies of 3,600 yuan per child for children under three years old starting January 1, 2025 [8] - The fertility optimization sector saw a collective high opening but ended with a "high open low close" trend, with the sector rising by only 0.18% after an initial surge [9][10] - Stocks like Beiyinmei and Aiyingshi opened strongly but fell significantly, while stocks in the dairy sector also experienced a similar pattern [10] Yajiang Hydropower Station - The Yajiang Hydropower Station saw a rebound in the afternoon, with stocks like Xining Special Steel and Tibet Tianlu hitting the daily limit [15] - The Yajiang Hydropower concept stocks rose over 2% by the end of the day, indicating a recovery in investor interest [14] Stablecoin Sector - The stablecoin concept stocks experienced a partial rebound, with companies like Hengbao Co. and Sifang Jichuang showing strong performance [19] - The sector had been quiet for about two weeks but is now looking for a significant catalyst to revive interest [21] Guotou Intelligent - Guotou Intelligent saw a significant rise, closing up over 18.5%, attributed to news regarding a special action by the Internet Information Office [25] - The company is reportedly working on AI fraud prevention services, with a potential market space exceeding 120 billion yuan if it covers 1 billion smartphone users [28]
育儿补贴政策落地 婴童概念表现活跃 七大概念股盘点(名单)
Zheng Quan Zhi Xing· 2025-07-29 07:56
Group 1: Policy Impact on Industry - The implementation of the child-rearing subsidy policy is expected to significantly lower family child-rearing costs and enhance birth intentions, particularly benefiting the maternal and infant industry and dairy sectors [2][3] - The national child-rearing subsidy will provide annual cash support of 3,600 yuan per child for families with children under three years old, starting from January 1, 2025, which is projected to benefit over 20 million families annually [1][2] Group 2: Market Growth Projections - The Chinese baby and toddler market is currently in a "golden period" of growth, with a market size expected to reach 4.2 trillion yuan in 2024, surpassing 5 trillion yuan by 2025, and potentially reaching 10 trillion yuan by 2030 [2] - The policy and consumption upgrades are anticipated to drive the industry into becoming the next trillion-level blue ocean market [2] Group 3: Key Companies in the Sector - Aiyingshi focuses on providing maternal and infant products for families with children aged 0-6, with a strong market presence in East China [3] - Haiziwang is a leading retailer in the maternal and infant goods sector, offering a wide range of products for families with children up to 6 years old [3] - Beingmate is a domestic leader in infant formula, recognized for its safety traceability system [3] - Huhulawa specializes in pediatric respiratory treatments and has a high market share in children's medication [4] - Xibu Muye operates in one of China's major pastoral areas and produces infant formula [3] - Huangshi Group is a champion in the water buffalo milk segment, developing specialized milk products for children [4] - David Medical is a leading company in infant care equipment, focusing on the development and production of essential medical devices for newborns [4]